Eisai cut U.S. sales force by 8%; Crucell halts shipments on sterility concerns;

@FiercePharma: U.S. Atty: GSK plant probe is 'ongoing.' Story | Follow @FiercePharma

Slideshow: Notorious Names in Biopharma. Slideshow

Special Report: Pharma's Biggest Flops. Report

> Eisai has trimmed its sales force in the U.S. by roughly eight percent since the end of March to deal with next month's expiration of patent protection there for its key Alzheimer's disease treatment, Aricept. Story

> Crucell put a temporary hold on all shipments of its liquid pentavalent vaccine Quinvaxem and its hepatitis B vaccine Hepavax-Gene because the sterile operation of a facility in Korea may have been compromised. Report

> Takeda Pharmaceutical and Daiichi Sankyo reported contrasting results for their fiscal first half, as Daiichi's strategy of focusing on the generic drug business set it apart from peers more seriously hurt by the patent cliff. Item

> Drug and food firm Otsuka plans to list its shares in Tokyo in early December after what will likely be one of the largest initial public offerings in Japan this year. Article

> Shire raised its 2010 earnings guidance again after booking bumper third-quarter sales of its medicines for rare diseases. Article

> Celgene's (CELG) third-quarter earnings jumped 30 percent, with adjusted results topping analysts' views, as the company's sales climbed; it also raised its 2010 forecast. Report

> Cephalon (CEPH.O) boosted its full-year earnings forecast range by 75 cents a share, helped by cost cutting, and provided a rosy outlook for 2011 after reporting a 38 percent jump in third-quarter profit. News

> FDA approved a new indication for Bristol-Myers Squibb's Sprycel (dasatinib) as a first-line treatment for a rare blood cancer called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML). FDA release

> Roche's (ROG.VX) cancer drug MabThera can now be used in Europe as a first line maintenance treatment for follicular lymphoma, a common form of blood cancer, broadening the drug's use. Item

> Japanese health regulators approved Pfizer's (PFE.N) Lyrica to treat a type of nerve pain called peripheral neuropathic pain. Story

Biotech News

> Almirall, Forest COPD drug misses goal in PhIII study. Story

> FDA approves Dainippon's Latuda for schizophrenia. Article

> Almirall, Forest COPD drug misses goal in PhIII study. Report

And Finally... Teva Pharmaceuticals said that $4.7 million in state aid helped convince it to put its new distribution facility in Philadelphia's Somerton neighborhood, where the company hopes to employ 500 people. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.